Targeting the Porcine Immune System--particulate Vaccines in the 21st Century

Overview

Journal Dev Comp Immunol

Specialty Allergy & Immunology

Date 2008 Sep 6

PMID 18771683

Citations 11

Authors

Kenneth C McCullough

Artur Summerfield

Affiliations

Soon will be listed here.

Abstract

During the last decade, the propagation of immunological knowledge describing the critical role of dendritic cells (DC) in the induction of efficacious immune responses has promoted research and development of vaccines systematically targeting DC. Based on the promise for the rational design of vaccine platforms, the current review will provide an update on particle-based vaccines of both viral and synthetic origin, giving examples of recombinant virus carriers such as adenoviruses and biodegradable particulate carriers. The viral carriers carry pathogen-associated molecular patterns (PAMP), used by the original virus for targeting DC, and are particularly efficient and versatile gene delivery vectors. Efforts in the field of synthetic vaccine carriers are focussing on decorating the particle surface with ligands for DC receptors such as heparan sulphate glycosaminoglycan structures, integrins, Siglecs, galectins, C-type lectins and toll-like receptors. The emphasis of this review will be placed on targeting the porcine immune system, but reference will be made to advances with murine and human vaccine delivery systems where information on DC targeting is available.

Citing Articles

Targeted Delivery of Nanovaccine to Dendritic Cells via DC-Binding Peptides Induces Potent Antiviral Immunity in vivo.

Lu Y, Liu Z, Li Y, Xu H, Fang W, He F Int J Nanomedicine. 2022; 17():1593-1608.

PMID: 35411142 PMC: 8994610. DOI: 10.2147/IJN.S357462.

The pig as a model for immunology research.

Pabst R Cell Tissue Res. 2020; 380(2):287-304.

PMID: 32356014 PMC: 7223737. DOI: 10.1007/s00441-020-03206-9.

Development of porcine circovirus 2 (PCV2) open reading frame 2 DNA vaccine with different adjuvants and comparison with commercial PCV2 subunit vaccine in an experimental challenge.

Park C, Jeong J, Choi K, Park S, Kang I, Chae C Can J Vet Res. 2017; 81(3):171-177.

PMID: 28725106 PMC: 5508387.

Self-Amplifying Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic Nanoparticles.

McCullough K, Milona P, Thomann-Harwood L, Demoulins T, Englezou P, Suter R Vaccines (Basel). 2015; 2(4):735-54.

PMID: 26344889 PMC: 4494254. DOI: 10.3390/vaccines2040735.

Memory T cell proliferative responses and IFN-γ productivity sustain long-lasting efficacy of a Cap-based PCV2 vaccine upon PCV2 natural infection and associated disease.

Ferrari L, Borghetti P, De Angelis E, Martelli P Vet Res. 2014; 45:44.

PMID: 24735253 PMC: 3999888. DOI: 10.1186/1297-9716-45-44.

References

Jackson T, Clark S, Berryman S, Burman A, Cambier S, Mu D . Integrin alphavbeta8 functions as a receptor for foot-and-mouth disease virus: role of the beta-chain cytodomain in integrin-mediated infection. J Virol. 2004; 78(9):4533-40. PMC: 387692. DOI: 10.1128/jvi.78.9.4533-4540.2004. View

Seth A, Yasutomi Y, Jacoby H, Callery J, Kaminsky S, Koff W . Evaluation of a lipopeptide immunogen as a therapeutic in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses. 2000; 16(4):337-43. DOI: 10.1089/088922200309214. View

Baudoux P, Carrat C, Besnardeau L, Charley B, Laude H . Coronavirus pseudoparticles formed with recombinant M and E proteins induce alpha interferon synthesis by leukocytes. J Virol. 1998; 72(11):8636-43. PMC: 110275. DOI: 10.1128/JVI.72.11.8636-8643.1998. View

Harwood L, Gerber H, Sobrino F, Summerfield A, McCullough K . Dendritic cell internalization of foot-and-mouth disease virus: influence of heparan sulfate binding on virus uptake and induction of the immune response. J Virol. 2008; 82(13):6379-94. PMC: 2447102. DOI: 10.1128/JVI.00021-08. View

Dawson M, Krauland E, Wirtz D, Hanes J . Transport of polymeric nanoparticle gene carriers in gastric mucus. Biotechnol Prog. 2004; 20(3):851-7. DOI: 10.1021/bp0342553. View

Wesley R, Lager K . Evaluation of a recombinant human adenovirus-5 vaccine administered via needle-free device and intramuscular injection for vaccination of pigs against swine influenza virus. Am J Vet Res. 2005; 66(11):1943-7. DOI: 10.2460/ajvr.2005.66.1943. View

Drillien R, Spehner D, Bohbot A, Hanau D . Vaccinia virus-related events and phenotypic changes after infection of dendritic cells derived from human monocytes. Virology. 2000; 268(2):471-81. DOI: 10.1006/viro.2000.0203. View

Panyam J, Labhasetwar V . Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55(3):329-47. DOI: 10.1016/s0169-409x(02)00228-4. View

Berinstein A, Roivainen M, Hovi T, Mason P, Baxt B . Antibodies to the vitronectin receptor (integrin alpha V beta 3) inhibit binding and infection of foot-and-mouth disease virus to cultured cells. J Virol. 1995; 69(4):2664-6. PMC: 188951. DOI: 10.1128/JVI.69.4.2664-2666.1995. View

10.

Bot A, Stan A, Inaba K, Steinman R, Bona C . Dendritic cells at a DNA vaccination site express the encoded influenza nucleoprotein and prime MHC class I-restricted cytolytic lymphocytes upon adoptive transfer. Int Immunol. 2000; 12(6):825-32. DOI: 10.1093/intimm/12.6.825. View

11.

Azad N, Rojanasakul Y . Vaccine delivery--current trends and future. Curr Drug Deliv. 2006; 3(2):137-46. DOI: 10.2174/156720106776359249. View

12.

Eyles J, Carpenter Z, Alpar H, Williamson E . Immunological aspects of polymer microsphere vaccine delivery systems. J Drug Target. 2004; 11(8-10):509-14. DOI: 10.1080/10611860410001670017. View

13.

Cui Z, Mumper R . The effect of co-administration of adjuvants with a nanoparticle-based genetic vaccine delivery system on the resulting immune responses. Eur J Pharm Biopharm. 2003; 55(1):11-8. DOI: 10.1016/s0939-6411(02)00129-7. View

14.

Dechecchi M, Tamanini A, Bonizzato A, Cabrini G . Heparan sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. Virology. 2000; 268(2):382-90. DOI: 10.1006/viro.1999.0171. View

15.

Crocker P, Varki A . Siglecs in the immune system. Immunology. 2001; 103(2):137-45. PMC: 1783234. DOI: 10.1046/j.0019-2805.2001.01241.x. View

16.

Rossmann M, He Y, Kuhn R . Picornavirus-receptor interactions. Trends Microbiol. 2002; 10(7):324-31. DOI: 10.1016/s0966-842x(02)02383-1. View

17.

Enjuanes L, Sola I, Alonso S, Escors D, Zuniga S . Coronavirus reverse genetics and development of vectors for gene expression. Curr Top Microbiol Immunol. 2004; 287:161-97. PMC: 7120368. DOI: 10.1007/3-540-26765-4_6. View

18.

Macpherson G, Kushnir N, Wykes M . Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev. 2000; 172:325-34. DOI: 10.1111/j.1600-065x.1999.tb01376.x. View

19.

Pan Q, He K, Huang K . Development of recombinant porcine parvovirus-like particles as an antigen carrier formed by the hybrid VP2 protein carrying immunoreactive epitope of porcine circovirus type 2. Vaccine. 2008; 26(17):2119-26. DOI: 10.1016/j.vaccine.2008.02.037. View

20.

Jilek S, Zurkaulen H, Pavlovic J, Merkle H, Walter E . Transfection of a mouse dendritic cell line by plasmid DNA-loaded PLGA microparticles in vitro. Eur J Pharm Biopharm. 2004; 58(3):491-9. DOI: 10.1016/j.ejpb.2004.03.038. View